Lems, W. F. http://orcid.org/0000-0002-6885-3953
Paccou, J.
Zhang, J.
Fuggle, N. R.
Chandran, M.
Harvey, N. C.
Cooper, C.
Javaid, K.
Ferrari, S.
Akesson, K. E.
Akesson, K.E.
Brandi, M.L.
Chandran, M.
Chevalley, T.
Cooper, C.
Fardellone, P.
Goemaere, S.
Harvey, N.C.
Holzer, G.
Javaid, M.K.
Lems, W.
Lewiecki, E.M.
Lyritis, G.
Napoli, N.
Paccou, J.
Silverman, S.
Sosa, M.
Thomas, T.
,
Article History
Received: 21 October 2020
Accepted: 16 December 2020
First Online: 21 January 2021
Compliance with ethical standards
:
: WFL: received fees for lectures and advisory boards from Amgen, Eli Lilly, UCB, Pfizer, Galapagos and Curaphar; JZ: no conflict of interest; NRF: no conflict of interest; NCH: reports consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. CC: received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. MKJ: received fees for lectures and advisory boards from Amgen, UCB, KLA: Amgen, Astellas, Chugai, Renapharma, UCB.